BlackRock’s Ambrx Biopharma Inc AMAM Stock Holding History

BlackRock’s Portfolio AMAM Stock Details AMAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-501,604	Closed	-$7.14M	–	5441
2023 Q4	$7.14M	Buy	+501,604	New	+$5.7M	﹤0.01%	3543
2022 Q4	–	Sell	-2,851,433	Closed	-$3.08M	–	5871
2022 Q3	$3.08M	Sell	2,851,433 -53	-0%	-$109	﹤0.01%	3971
2022 Q2	$7.56M	Hold	2,851,486	–	–	﹤0.01%	3640
2022 Q1	$11.7M	Sell	2,851,486 -18,000	-0.6%	-$92.1K	﹤0.01%	3491
2021 Q4	$25.9M	Buy	2,869,486 +2,049,265	+250%	+$22.9M	﹤0.01%	3125
2021 Q3	$11.1M	Sell	820,221 -30,455	-4%	-$548K	﹤0.01%	3631
2021 Q2	$16.7M	Buy	+850,676	New	+$14.5M	﹤0.01%	3412

BlackRock's AMAM Position: Q1 2024 in Review

BlackRock sold out of Ambrx Biopharma Inc (AMAM) in Q1 2024, closing a stake of 501,604 shares — an estimated $7.14M sold.

BlackRock first reported a position in AMAM in Q2 2021 and held it in 7 quarters. The position peaked at $25.9M in Q4 2021. 0 funds tracked by Wall St. Rank hold AMAM as of Q1 2024.

BlackRock reported no remaining Ambrx Biopharma Inc position as of Q1 2024 after selling out during the quarter.
BlackRock sold 501,604 Ambrx Biopharma Inc shares in Q1 2024, an estimated $7.14M.
BlackRock first reported a position in Ambrx Biopharma Inc in Q2 2021 and held it in 7 quarters.
BlackRock's Ambrx Biopharma Inc position peaked at $25.9M in Q4 2021.
0 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q1 2024.

Based on BlackRock's 13F filing for Q1 2024, filed 10 May 2024.